DK1819830T3 - Fremgangsmåder til antistofgenerering - Google Patents

Fremgangsmåder til antistofgenerering

Info

Publication number
DK1819830T3
DK1819830T3 DK05851359.9T DK05851359T DK1819830T3 DK 1819830 T3 DK1819830 T3 DK 1819830T3 DK 05851359 T DK05851359 T DK 05851359T DK 1819830 T3 DK1819830 T3 DK 1819830T3
Authority
DK
Denmark
Prior art keywords
antibody
amino acid
methods
acid sequence
substitutable position
Prior art date
Application number
DK05851359.9T
Other languages
English (en)
Inventor
Fernando Jose Rebelo Do Couto
Kristin B Hendricks
Stacey Ellen Wallace
Guo-Liang Yu
Original Assignee
Epitomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitomics Inc filed Critical Epitomics Inc
Application granted granted Critical
Publication of DK1819830T3 publication Critical patent/DK1819830T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
DK05851359.9T 2004-11-08 2005-11-02 Fremgangsmåder til antistofgenerering DK1819830T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/984,473 US7462697B2 (en) 2004-11-08 2004-11-08 Methods for antibody engineering
PCT/US2005/039930 WO2006050491A2 (en) 2004-11-08 2005-11-02 Methods for antibody engineering

Publications (1)

Publication Number Publication Date
DK1819830T3 true DK1819830T3 (da) 2011-07-04

Family

ID=36316567

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05851359.9T DK1819830T3 (da) 2004-11-08 2005-11-02 Fremgangsmåder til antistofgenerering

Country Status (12)

Country Link
US (5) US7462697B2 (da)
EP (1) EP1819830B1 (da)
JP (2) JP2008518619A (da)
CN (2) CN101080496A (da)
AT (1) ATE507302T1 (da)
CA (2) CA2585742C (da)
DE (1) DE602005027737D1 (da)
DK (1) DK1819830T3 (da)
ES (1) ES2362792T3 (da)
HK (1) HK1200854A1 (da)
PT (1) PT1819830E (da)
WO (1) WO2006050491A2 (da)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
MX2008014692A (es) * 2006-05-19 2009-08-18 Alder Biopharmaceuticals Inc Metodo de cultivo para obtener una poblacion clonal de celulas b especificas de antigeno.
WO2008110348A1 (en) * 2007-03-12 2008-09-18 Esbatech Ag Sequence based engineering and optimization of single chain antibodies
AU2013204593B2 (en) * 2007-05-21 2016-01-21 Alderbio Holdings Llc Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
TW201531484A (zh) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗ＴＮＦ-α之抗體及其用途
TWI561530B (en) 2007-05-21 2016-12-11 Alderbio Holdings Llc Antibodies to il-6 and use thereof
TWI501976B (zh) * 2007-05-21 2015-10-01 Alder Biopharmaceuticals Inc 抗ＴＮＦ－α之抗體及其用途
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
KR101530723B1 (ko) * 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
PL2158315T3 (pl) * 2007-06-25 2016-10-31 Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych
AU2008290607B2 (en) * 2007-08-20 2013-11-14 Glaxo Group Limited Production method
DK3059246T3 (da) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modificeret konstant region i et antistof
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
WO2009120178A1 (en) * 2008-03-26 2009-10-01 Epitomics, Inc. Anti-vegf antibody
US9365644B2 (en) * 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
ES2687259T5 (es) * 2008-06-25 2022-10-14 Novartis Ag Anticuerpos estables y solubles que inhiben TNF
AU2016273957C1 (en) * 2008-06-25 2019-04-18 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
HUE032894T2 (hu) 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9079942B2 (en) * 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
EP3674317A1 (en) 2009-03-19 2020-07-01 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
CA2757114C (en) 2009-03-30 2019-05-21 Universite De Lausanne Preparation of isolated agonist anti-edar monoclonal antibodies
US8765916B2 (en) 2009-04-29 2014-07-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. ERG monoclonal antibodies
US20100317539A1 (en) * 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
EP2481752B1 (en) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
EP2504031A4 (en) 2009-11-24 2013-06-26 Alderbio Holdings Llc ANTI-IL-6 ANTIBODIES AND THEIR USE
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
HUE043556T2 (hu) 2009-12-10 2019-09-30 Regeneron Pharma Nehézlánc antitesteket elõállító egerek
KR101593262B1 (ko) * 2009-12-22 2016-02-11 에프. 호프만-라 로슈 아게 서열 의존 응집
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
CN101928345B (zh) * 2010-06-21 2012-08-29 中国科学技术大学 一种人源化抗体及其人源化改造方法
US9085621B2 (en) 2010-09-10 2015-07-21 Apexigen, Inc. Anti-IL-1β antibodies
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
TW201631153A (zh) 2010-11-17 2016-09-01 中外製藥股份有限公司 具有替代血液凝固第ｖｉｉｉ因子之功能的多重專一性抗原結合分子
CA2818813C (en) 2010-11-23 2020-10-06 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
US8753634B2 (en) 2011-03-03 2014-06-17 Apexigen, Inc. Anti-IL-6 receptor antibodies and methods of use
CN103635488B (zh) 2011-04-29 2016-12-14 埃派斯进有限公司 抗-cd40抗体及其使用方法
US9580496B2 (en) * 2011-05-06 2017-02-28 Nexvet Australia Pty Ltd Therapeutic canine immunoglobulins and methods of using same
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
BR112013028655B1 (pt) * 2011-05-06 2022-08-16 Zoetis Services Llc Anticorpos anti-fator de crescimento neuronal, composição farmacêutica compreendendo os mesmos e kit para o tratamento de dor em felinos
CN103747807B (zh) 2011-07-05 2016-12-07 比奥阿赛斯技术有限公司 P97‑抗体缀合物和使用方法
EP2732269B1 (en) 2011-07-12 2017-10-18 Epitomics, Inc. Facs-based method for obtaining an antibody sequence
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
PT2739649T (pt) 2011-08-05 2018-01-03 Bioasis Technologies Inc Fragmentos de p97 com atividade de transferência
US9988687B2 (en) 2011-09-20 2018-06-05 The George Washington Univeristy Companion diagnostics for cancer and screening methods to identify companion diagnostics for cancer based on splicing variants
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2785742B1 (en) 2011-11-02 2020-01-08 Apexigen, Inc. Anti-kdr antibodies and methods of use
US9376485B2 (en) * 2012-02-29 2016-06-28 The Brigham And Women's Hospital, Inc. Neutralizing antibody for epstein barr virus-associated disease
AU2013296557B2 (en) 2012-07-31 2019-04-18 Bioasis Technologies Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
CN104981482A (zh) * 2012-12-05 2015-10-14 迪塔莱斯有限公司 双靶向作用
CN103145834B (zh) * 2013-01-17 2015-03-18 广州泰诺迪生物科技有限公司 一种抗体人源化改造方法
ES2774549T3 (es) 2013-03-13 2020-07-21 Bioasis Technologies Inc Fragmentos de P97 y usos de los mismos
WO2014159430A1 (en) 2013-03-14 2014-10-02 Apexigen, Inc. Anti-rankl antibodies and methods of use
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015026606A1 (en) 2013-08-19 2015-02-26 Epitomics, Inc. Antibody identification by lineage analysis
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
EP3050896B1 (en) 2013-09-27 2021-07-07 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
MX2016006561A (es) * 2013-11-19 2016-12-12 Fredax Ab Anticuerpo anti-calicreina-2 humanizado.
AU2014360539A1 (en) 2013-12-03 2016-06-23 President And Fellows Of Harvard College Methods and reagents for the assessment of gestational diabetes
CA2936805C (en) 2014-01-17 2024-02-20 Minomic International Ltd. Cell surface prostate cancer antigen for diagnosis
BR112016017933A2 (pt) 2014-02-03 2017-10-10 Bioasis Technologies Inc ?proteínas de fusão p97?
WO2015126729A1 (en) 2014-02-19 2015-08-27 Bioasis Technologies, Inc. P97-ids fusion proteins
EP3134439B1 (en) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
WO2015168521A2 (en) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. P97-polynucleotide conjugates
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR101618458B1 (ko) 2014-11-28 2016-05-10 강원대학교산학협력단 항체에서 항원-항체 결합력과 양의 상관관계를 갖는 아미노산 서열에 대한 정보를 얻는 방법
SG10201710322VA (en) 2014-12-19 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
CN107108726A (zh) 2014-12-19 2017-08-29 中外制药株式会社 抗‑肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法
GB201500464D0 (en) 2015-01-12 2015-02-25 Crescendo Biolog Ltd Method of producing optimised therapeutic molecules
CN114773469A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
AU2016218983A1 (en) 2015-02-13 2017-08-10 Biommune Technologies Inc. Antibodies to L-type voltage gated channels and related methods
TW202339800A (zh) 2015-02-27 2023-10-16 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
SG11201807936VA (en) 2016-03-14 2018-10-30 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
AU2017285995B2 (en) * 2016-06-14 2023-11-30 Agency For Science, Technology And Research PRL3 antibody
US20190352426A1 (en) 2016-08-03 2019-11-21 Achaogen, Inc. Plazomicin antibodies and methods of use
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
US20180244785A1 (en) 2017-01-09 2018-08-30 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
US11767520B2 (en) 2017-04-20 2023-09-26 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11078283B2 (en) 2018-01-17 2021-08-03 Apexigen, Inc. Anti-PD-L1 antibodies and methods of use
JP2021525779A (ja) 2018-06-08 2021-09-27 ヴェンタナ メディカル システムズ， インク． 機能性および製造可能性を改善するための普遍的なまたは正規化された抗体フレームワーク
EP3813867A1 (en) 2018-07-22 2021-05-05 Bioasis Technologies Inc. Treatment of lymmphatic metastases
RS63943B1 (sr) * 2018-07-31 2023-02-28 Heidelberg Pharma Res Gmbh Humanizovana antitela protiv psma
EP3954393A1 (en) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Combination therapies for delivery across the blood brain barrier
WO2022223028A1 (zh) * 2021-04-23 2022-10-27 上海君实生物医药科技股份有限公司 抗BLyS抗体、其药物组合物及其用途
EP4296279A1 (en) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin (ttr) binding proteins and uses thereof
CN115819575B (zh) * 2022-08-24 2023-06-27 武汉爱博泰克生物科技有限公司 针对人肿瘤坏死因子-α的单克隆抗体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6093853A (en) 1997-07-04 2000-07-25 Nok Corporation Phenylenediamine derivative, production method thereof and antioxidant for rubber using it as effective constituent
US6342587B1 (en) 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
US7115716B2 (en) 2001-11-19 2006-10-03 Eli Lilly And Company Tumor specific monoclonal antibodies
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
DE60329589D1 (de) * 2002-04-30 2009-11-19 Kyowa Hakko Kirin Co Ltd Antikörper gegen den humanen "insulin-like" wachstumsfaktor
WO2004016740A2 (en) 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
JP4804340B2 (ja) * 2003-01-17 2011-11-02 ダニスコ エイ／エス 脂質アシルトランスフェラーゼの使用
AU2004213053C1 (en) * 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20070026398A1 (en) * 2003-03-03 2007-02-01 Farnsworth Amanda L Protein tyrosine phosphatase-prl-1 a a marker and therapeutic target for pancreatic cancer
US20050033031A1 (en) * 2003-08-07 2005-02-10 Couto Fernando Jose Rebelo Do Methods for humanizing rabbit monoclonal antibodies
US8148335B2 (en) * 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering

Also Published As

Publication number Publication date
CN101080496A (zh) 2007-11-28
CN103980362A (zh) 2014-08-13
JP2008518619A (ja) 2008-06-05
JP2012095654A (ja) 2012-05-24
HK1200854A1 (en) 2015-08-14
US20120329069A1 (en) 2012-12-27
CA2585742A1 (en) 2006-05-11
CA2901238A1 (en) 2006-05-11
PT1819830E (pt) 2011-07-20
US7462697B2 (en) 2008-12-09
ES2362792T3 (es) 2011-07-13
ATE507302T1 (de) 2011-05-15
JP5096611B2 (ja) 2012-12-12
CA2901238C (en) 2020-03-24
US20060099204A1 (en) 2006-05-11
CA2585742C (en) 2016-04-12
EP1819830B1 (en) 2011-04-27
US8404816B2 (en) 2013-03-26
US20090155824A1 (en) 2009-06-18
DE602005027737D1 (de) 2011-06-09
US20150038370A1 (en) 2015-02-05
US10613094B2 (en) 2020-04-07
WO2006050491A3 (en) 2006-12-28
US7960517B2 (en) 2011-06-14
WO2006050491A2 (en) 2006-05-11
EP1819830A4 (en) 2009-03-11
EP1819830A2 (en) 2007-08-22
US20120003671A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
DK1819830T3 (da) Fremgangsmåder til antistofgenerering
NL300919I2 (nl) Brodalumab
TW200626614A (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
MX2020001873A (es) Agentes de union.
DK1716178T3 (da) Mindre immunogene bindingsmolekyler
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
BRPI0511910A (pt) anticorpos antil-il-13 e complexos
HRP20160209T1 (hr) Antigenski vežuća molekula koja se može višekratno vezati na dva ili više antigena
TN2014000120A1 (en) Cd27l antigen binding proteins
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
DK1697421T3 (da) Bispecifikke antistoffer
WO2008036688A3 (en) Optimized antibodies that target hm1.24
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
ATE452147T1 (de) Antikörper mit korrigierten cdr
WO2008133641A3 (en) Antibodies directed to gpnmb and uses thereof
WO2009088924A3 (en) Methods and materials for targeted affinity enhancement
EA200970694A1 (ru) ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ
AU2013310924A8 (en) Method for producing antibody molecules having inter-species, intra-target cross-reactivity
WO2008065384A3 (en) Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor
WO2008081331A3 (en) Enhancing the level of antibody expression by framework re-engineering
ATE531799T1 (de) Nukleinsäuremolekül mit fähigkeit zur bindung an aus kaninchen stammenden igg-antikörper
WO2008140580A3 (en) Specific antibody selection by selective elution conditions
TH87431B (th) แอนติบอดีชนิดแอนติ-il-12, เอพิโทป, สารผสม, วิธี และการใช้
TH101183B (th) แอนทิบอดีและตัวควบคู่ภูมิคุ้มกันและการใช้งานด้วยเหตุนั้น